Activated oncogenes are the genetic drivers of human cancer progression. Oncogenes become activated by structural DNA alterations, which include: Point mutations, small insertions or deletions, copy number variations and gene translocations/fusion. Cancer drugs are most effective when they target activated oncogenes and matching the right drug to the right target in the right patient is critical for a positive outcome. The future of molecular oncology depends on the ability to diagnose the ONCOGENE SIGNATURE in individual cancer patient. Recent developments in the sequencing technologies and large-scale comprehensive genomic profiling studies continue to identify recurrent mutations in a subset of genes indicating their role in disease progression. Today, due to the technological advances and scientific breakthroughs cancer treatment is going through a fundamental transition where the conventional treatment using cytotoxic chemicals is being replaced by less toxic and targeted drugs based on the specific genetic alteration. The future of molecular oncology depends on the ability to accurately establish the oncogene signature in individual cancer patients. At ITOS Oncology, we use cutting edge Next Generation Sequencing (NGS) technology to identify specific molecular aberrations driving cancer in individual patients. The ability to detect complex oncogene signatures in individual cancer is vital for designing therapeutic strategies with single or multiple targeted agents.